Innoviva Inc INVA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/16/24 EDT
15.98quote price arrow up+0.14 (+0.88%)
Volume
730,641
52 week range
12.22 - 16.86
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close15.98
  • 52 Week High16.86
  • 52 Week High Date01/04/24
  • 52 Week Low12.22
  • 52 Week Low Date11/01/23

Key Stats

  • Market Cap999.045M
  • Shares Out62.52M
  • 10 Day Average Volume0.58M
  • Dividend-
  • Dividend Yield-
  • Beta0.58
  • YTD % Change-1.25

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close15.98
  • 52 Week High16.86
  • 52 Week High Date01/04/24
  • 52 Week Low12.22
  • 52 Week Low Date11/01/23
  • Market Cap999.045M
  • Shares Out62.52M
  • 10 Day Average Volume0.58M
  • Dividend-
  • Dividend Yield-
  • Beta0.58
  • YTD % Change-1.25

RATIOS/PROFITABILITY

  • EPS (TTM)2.19
  • P/E (TTM)7.30
  • Fwd P/E (NTM)19.02
  • EBITDA (TTM)148.166M
  • ROE (TTM)28.67%
  • Revenue (TTM)311.59M
  • Gross Margin (TTM)86.12%
  • Net Margin (TTM)58.21%
  • Debt To Equity (MRQ)63.49%

EVENTS

  • Earnings Date07/31/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Innoviva Inc

 

Content From Our Affiliates

Profile

MORE
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of...
Pavel Raifeld
Chief Executive Officer
Stephen Basso
Chief Financial Officer
Marianne Zhen CPA
Chief Accounting Officer
Address
1350 OLD BAYSHORE HIGHWAY, SUITE 400
Burlingame, CA
94010
United States

Top Peers

SYMBOLLASTCHG%CHG
IRWD
Ironwood Pharmaceuticals Inc
6.64+0.08+1.22%
CSTL
Castle Biosciences Inc
24.22-0.14-0.57%
COLL
Collegium Pharmaceutical Inc
33.67-0.31-0.91%
OCUL
Ocular Therapeutix Inc
6.27-0.02-0.32%
AMRN
Amarin Corporation PLC
0.9124-0.0235-2.511%